Physician profile
Michael Rogachevsky
NPI 1427103308
$21,254.92
in general payments reported to CMS, 2019-2025
27 companies · $4,659 in 2025
The $4,659 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,489 · 2020: $1,703 · 2021: $2,833 · 2022: $2,957 · 2023: $3,011 · 2024: $3,603 · 2025: $4,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,260.68 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,431.99 | 2021-2025 | Vraylar |
| Alkermes, INC. | $2,781.06 | 2020-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $2,429.59 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,028.99 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,320.13 | 2019-2022 | |
| Lundbeck LLC | $1,190.39 | 2019-2025 | Rexulti |
| Allergan, INC. | $1,154.20 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,003.15 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $953.34 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $863.60 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $839.72 | 2021-2025 | Azstarys |
| Almatica Pharma LLC | $782.55 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Bausch Health US, LLC | $622.49 | 2019-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $294.31 | 2019-2025 | Adzenys Xr-Odt, Exxua, Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $293.90 | 2022-2025 | Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $262.08 | 2019-2025 | Austedo, Uzedy, Austedo Xr |
| Adlon Therapeutics L.P. | $205.95 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $196.39 | 2019 | |
| Shire North American Group INC | $130.86 | 2019 | |
| Eisai INC. | $116.91 | 2021 | |
| Noven Therapeutics, LLC | $98.84 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $82.59 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $54.98 | 2019 | |
| Neurocrine Biosciences, INC. | $36.74 | 2025 | |
| Sage Therapeutics, LLC | $30.92 | 2025 | Zurzuvae |
| Owp Pharmaceuticals, INC. | $25.00 | 2024 | Subvenite |
| Biogen, INC. | $24.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rogachevsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.